IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 11,404 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 11,404 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were purchased at an average cost of $0.94 per share, with a total value of $10,719.76. Following the purchase, the insider directly owned 917,052 shares of the company’s stock, valued at approximately $862,028.88. This represents a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Up 29.4%

NASDAQ:IRIX opened at $0.88 on Thursday. The business’s 50-day moving average price is $0.73 and its 200 day moving average price is $0.95. The firm has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. Sell-side analysts expect that IRIDEX Corporation will post -0.12 EPS for the current year.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Institutional Investors Weigh In On IRIDEX

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in shares of IRIDEX in the 2nd quarter valued at $29,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the 2nd quarter worth about $30,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX during the 1st quarter worth about $35,000. United Capital Financial Advisors LLC acquired a new stake in IRIDEX during the 2nd quarter worth about $41,000. Finally, Thompson Davis & CO. Inc. raised its holdings in IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 18,944 shares during the period. 20.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.00.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.